PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer.

J Thorac Oncol · 2015 · PMC4276572 · PMID 25371077

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Hemorrhage was numerically higher in the Pem+Cb arm (1.2% versus 0.00%), and thrombosis/embolism was numerically higher in the Pac+Cb+Bev arm (0.0% versus 2.4%); these differences did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.